{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:05:04Z","timestamp":1789445104040,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"UPM National Institutes of Health","award":["Research Fund 2022"],"award-info":[{"award-number":["Research Fund 2022"]}]},{"name":"Push One UPCM Class 1967 Postgraduate Studies Programme Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01171-7","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:32:54Z","timestamp":1782556374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of oral ivermectin, topical permethrin, and combination in the treatment of patients with classic scabies: systematic review and network meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Rowena F.","family":"Genuino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Christina Filomena R.","family":"Batac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence Pio Rey C.","family":"Yacapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen L.","family":"Dofitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Anne G.","family":"Ednalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Isabela P.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Bettina Teresa G.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis R.","family":"Capule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Fernando B.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann J.","family":"Ladia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaya P.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailyn M.","family":"Yabes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiel Nazer C.","family":"Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stephanie Fay S.","family":"Cagayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1171_CR1","unstructured":"Institute for Health Metrics and Evaluation. Global Burden of Disease. 2019. https:\/\/vizhub.healthdata.org\/gbd-compare\/%0D%0A. Accessed 21 Jun 2021."},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/jpc.13851","volume":"54","author":"S Thornley","year":"2018","unstructured":"Thornley S, Marshall R, Jarrett P, Sundborn G, Reynolds E, Schofield G. Scabies is strongly associated with acute rheumatic fever in a cohort study of Auckland children. J Paediatr Child Health. 2018;54:625\u201332.","journal-title":"J Paediatr Child Health"},{"key":"1171_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/jpc.14697","volume":"56","author":"S Thornley","year":"2020","unstructured":"Thornley S, King R, Marshall R, Oakley A, Sundborn G, Harrower J, et al. How strong is the relationship between scabies and acute rheumatic fever? An analysis of neighbourhood factors. J Paediatr Child Health. 2020;56:600\u20136.","journal-title":"J Paediatr Child Health"},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.12099","volume":"28","author":"SD Chung","year":"2014","unstructured":"Chung SD, Wang KH, Huang CC, Lin HC. Scabies increased the risk of chronic kidney disease: a 5-year follow-up study. J Eur Acad Dermatol Venereol. 2014;28:286\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1171_CR5","unstructured":"The Australian Healthy Skin Consortium. National Healthy Skin Guideline for the Prevention, Treatment and Public Health Control of Impetigo, Scabies, Crusted Scabies and Tinea for Indigenous Populations and Communities in Australia (1st edition). 2018."},{"key":"1171_CR6","doi-asserted-by":"crossref","unstructured":"Anna Banerji; Canadian Paediatric Society, First Nations I and MHC. Scabies: CPS position statement. Paediatr Child Health. 2015;20:395\u20138.","DOI":"10.1093\/pch\/20.7.395"},{"key":"1171_CR7","first-page":"1160","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter C, Feldmeier H, F\u00f6lster-Holst R, Geisel B, Klinke-Rehbein S, Nast A, et al. S1 guidelines on the diagnosis and treatment of scabies \u2013 short version Cord. J Ger Soc Dermatol. 2016;14:1160\u201371.","journal-title":"J Ger Soc Dermatol"},{"key":"1171_CR8","unstructured":"Clinical Effectiveness Group British Association for Sexual Health and HIV. 2016 UK National Guideline on the Management of Scabies. 2016."},{"key":"1171_CR9","doi-asserted-by":"crossref","unstructured":"La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R. Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis. 2009;3.","DOI":"10.1371\/journal.pntd.0000444"},{"key":"1171_CR10","doi-asserted-by":"publisher","unstructured":"Bernigaud C, Fernando DD, Lu H, Taylor S, Hartel G, Guillot J, et al. In vitro ovicidal activity of current and under-development scabicides: which treatments kill scabies eggs? Br J Dermatol. 2020;182(2):511\u20133. https:\/\/doi.org\/10.1111\/bjd.18517.\u00a0PubMed PMID: 31508811.","DOI":"10.1111\/bjd.18517"},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1093\/emboj\/16.19.5867","volume":"16","author":"JA Dent","year":"1997","unstructured":"Dent JA, Davis MW, Avery L. avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997;16:5867.","journal-title":"EMBO J"},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/jdv.14351","volume":"31","author":"CM Salavastru","year":"2017","unstructured":"Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31:1248\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1171_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/1346-8138.13896","volume":"44","author":"N Ishii","year":"2017","unstructured":"Ishii N, Asai T, Asahina A, Ishiko A, Imamura H, Kato T, et al. Guideline for the diagnosis and treatment of scabies in Japan (third edition): Executive Committee of Guideline for the Diagnosis and Treatment of Scabies. J Dermatol. 2017;44:991\u20131014.","journal-title":"J Dermatol"},{"key":"1171_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations Rep. 2021;70:1.","journal-title":"MMWR Recommendations Rep"},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jaad.2019.01.004","volume":"80","author":"K Thadanipon","year":"2019","unstructured":"Thadanipon K, Anothaisintawee T, Rattanasiri S, Thakkinstian A, Attia J. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019;80:1435\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR16","doi-asserted-by":"crossref","unstructured":"Baudou E, Durrieu G, Andre F, Gandia P, Durand C, Cunat S. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020;383.","DOI":"10.1056\/NEJMc1917344"},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","volume":"98","author":"RE Chandler","year":"2018","unstructured":"Chandler RE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98:382\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"1171_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0009354","volume":"15","author":"JT Campillo","year":"2021","unstructured":"Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in Sub-Saharan Africa and in the rest of the world. PLoS Negl Trop Dis. 2021;15:1\u201318.","journal-title":"PLoS Negl Trop Dis"},{"key":"1171_CR19","unstructured":"Austrian Society of Dermatology and Venereology. Skabies Therapiemanagement [Internet]. 2019 [cited 2023 Oct 24]. Available from: https:\/\/www.oegstd.at\/net\/index.php\/information\/archiv\/skabies-therapiemanagement. Accessed 1 Mar 2023."},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaad.2017.09.006","volume":"78","author":"A Dhana","year":"2018","unstructured":"Dhana A, Yen H, Okhovat JP, Cho E, Keum NN, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:194\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR21","first-page":"757","volume":"113","author":"C Dressler","year":"2016","unstructured":"Dressler C, Rosumeck S, Sunderk\u00f6tter C, Werner RN, Nast A. The treatment of scabies: a systematic review of randomized controlled trials. Dtsch Arztebl Int. 2016;113:757\u201362.","journal-title":"Dtsch Arztebl Int"},{"key":"1171_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012994.pub2","author":"S Rosumeck","year":"2018","unstructured":"Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Reviews. 2018. https:\/\/doi.org\/10.1002\/14651858.CD012994.pub2.","journal-title":"Cochrane Database Syst Reviews"},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/tmi.13198","volume":"24","author":"PJ May","year":"2019","unstructured":"May PJ, Tong SYC, Steer AC, Currie BJ, Andrews RM, Carapetis JR, et al. Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Trop Med Int Health. 2019;24:280\u201393.","journal-title":"Trop Med Int Health"},{"key":"1171_CR24","first-page":"7","volume":"31","author":"RF Genuino","year":"2022","unstructured":"Genuino RF, Christina M, Batac FR, Capule FR, Ednalino KAG, Garcia FB, et al. Comparative efficacy and safety of oral ivermectin, topical permethrin, and its combination in thetreatment of scabies: a systematic literature review. J Phil Dermatol Soc. 2022;31:7\u201319.","journal-title":"J Phil Dermatol Soc"},{"key":"1171_CR25","unstructured":"Wankhade P, Tamboli S, Deshmukh J, Rathode P, Domple V, Vikas D. A comparative study of topical permethrin, oral ivermectin and combination of permethrin with ivermectin in patients of scabies. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN. 2016;15:67\u201372."},{"key":"1171_CR26","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JPTSG. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions versi."},{"key":"1171_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jrsm.1195","volume":"7","author":"O Efthimiou","year":"2016","unstructured":"Efthimiou O, Debray TPA, van Valkenhoef G, Trelle S, Panayidou K, Moons KGM, et al. Get real in Network Meta-analysis: a review of the methodology. Res Synth Methods. 2016;7:236\u201363.","journal-title":"Res Synth Methods"},{"key":"1171_CR28","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"1171_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"1171_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10:39.","journal-title":"Syst Rev"},{"key":"1171_CR32","unstructured":"Veritas Health Innovation. Covidence systematic review software."},{"key":"1171_CR33","unstructured":"Cochrane Review Group. Risk of Bias 2 Cochrane Review Group Starter Pack Risk of Bias 2 CRG Starter Pack 2. 2022."},{"key":"1171_CR34","unstructured":"The Cochrane Collaboration. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). 2019; July:1\u201324."},{"key":"1171_CR35","unstructured":"RStudio Team. RStudio: Integrated Development for R. RStudio, PBC, Boston MA. 2020. https:\/\/posit.co\/. Accessed 9 Feb 2023."},{"key":"1171_CR36","unstructured":"R\u00fccker GUKKJEODAPTSG. R netmeta package: Network Meta-Analysis using Frequentist Methods Version 2.7-0 Date 2022-12-21. 2022."},{"key":"1171_CR37","unstructured":"Mann J, Boughton S. Policy for managing potentially problematic studies: implementation guidance. 2021."},{"key":"1171_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/d41586-019-03959-6","volume":"577","author":"A Grey","year":"2020","unstructured":"Grey A, Bolland MJ, Avenell A, Klein AA. Gunsalus & CK. Check for publication integrity before misconduct. Nature. 2020;577:167\u20139.","journal-title":"Nature"},{"key":"1171_CR39","first-page":"1","volume":"349 September","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349 September:1\u201310.","journal-title":"BMJ"},{"key":"1171_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol"},{"key":"1171_CR41","unstructured":"Iranian Registry of Clinical Trials. Effect of Malation lotion on scabies in comparison with permethrin cream 5% [Internet]. Trial ID: IRCT2014110110203N5. Tehran: Iranian Registry of Clinical Trials; [cited 2026 Jun 14]. Available from: Effect of Malation lotion on scabies in comparison with permethrin cream 5%. 2014. https:\/\/en.irct.ir\/trial\/10665IRCT2014110110203N5"},{"key":"1171_CR42","unstructured":"Abdel-Raheem. 2016 RCT trial registry record. PACTR201505001116484. 2015. https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=1116. Accessed 1 Mar 2023."},{"key":"1171_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5455\/2319-2003.ijbcp20131224","volume":"2","author":"S Chhaiya","year":"2013","unstructured":"Chhaiya S, Patel V, Dave J, Mehta D. To study cost effectiveness of topical permethrin versus oral ivermectin in patients of uncomplicated scabies. Int J Basic Clin Pharmacol. 2013;2:799.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"1171_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/09546634.2016.1151855","volume":"27","author":"TA Abdel-Raheem","year":"2016","unstructured":"Abdel-Raheem TA, M\u00e9abed EMH, Nasef GA, Abdel Wahed WY, Rohaim RMA. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatol Treat. 2016;27:473\u20139.","journal-title":"J Dermatol Treat"},{"key":"1171_CR45","first-page":"57","volume":"5","author":"G Aggarwal","year":"2014","unstructured":"Aggarwal G, K RP, Gupta VP. Comparative study to test efficacy of topical permethrin and oral ivermectin in the management of scabies- a prospective randomized, single blinded controlled study. Natl J Integr Res Med. 2014;5:57\u201360.","journal-title":"Natl J Integr Res Med"},{"key":"1171_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/dth.12310","volume":"29","author":"HM Ahmad","year":"2016","unstructured":"Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther. 2016;29:58\u201363.","journal-title":"Dermatol Ther"},{"key":"1171_CR47","first-page":"670","volume":"9","author":"AD Al Jaff","year":"2019","unstructured":"Al Jaff AD, Amin MHM. Comparison the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Res J Pharm Biol Chem Sci. 2019;9:670\u20136.","journal-title":"Res J Pharm Biol Chem Sci"},{"key":"1171_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-4362.1992.tb03958.x","volume":"31","author":"M Amer","year":"1992","unstructured":"Amer M. Permethrin versus crotamiton versus lindane in the treatment of scabies. Int J Dermatol. 1992;31:357\u20138.","journal-title":"Int J Dermatol"},{"key":"1171_CR49","first-page":"69","volume":"13","author":"P Amerio","year":"2003","unstructured":"Amerio P, Capizzi RMM. Efficacy and tolerability of natural synergised pyrethrins in a new thermo labile foam formulation in topical treatment of scabies: a prospective, randomised, investigator- blinded, comparative trial vs. permethrin cream. Europ J Dermatol. 2003;13:69\u201371.","journal-title":"Europ J Dermatol"},{"key":"1171_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.48882","volume":"41","author":"NP Bachewar","year":"2009","unstructured":"Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41:9\u201314.","journal-title":"Indian J Pharmacol"},{"key":"1171_CR51","first-page":"2","volume":"10","author":"S Bokhari","year":"2000","unstructured":"Bokhari S, Mann MIJ. A randomized, controlled trial to compare the efficiency of 1% lindane (scabene) cream and 5% permethrin (lotrix) cream for the treatment of scabies. J Pak Assoc Dermatol. 2000;10:2\u20134.","journal-title":"J Pak Assoc Dermatol"},{"key":"1171_CR52","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1046\/j.1440-1754.2002.00015.x","volume":"38","author":"PA Brooks","year":"2002","unstructured":"Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health. 2002;38:401\u20134.","journal-title":"J Paediatr Child Health"},{"key":"1171_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4103\/0378-6323.100571","volume":"78","author":"SB Chhaiya","year":"2012","unstructured":"Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78:605\u201310.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1171_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/archderm.135.6.651","volume":"135","author":"EN Chouela","year":"1999","unstructured":"Chouela EN, Abelda\u00f1o AM, Pellerano G, la Forgia M, Papale RM, Garsd A, et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol. 1999;135:651\u20135.","journal-title":"Arch Dermatol"},{"key":"1171_CR55","first-page":"3","volume":"3","author":"M Daneshpajooh","year":"1999","unstructured":"Daneshpajooh M. The comparison of oral ivermectin and topical gamma-benzene hexachloride 1% in treatment of scabies (Persian). Iran J Dermatol. 1999;3:3.","journal-title":"Iran J Dermatol"},{"key":"1171_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0019-5154.27981","volume":"51","author":"S Das","year":"2006","unstructured":"Das S, Chatterjee T, Banerji G, Biswas I. Evaluation of the commonest site, demographic profile and most effective therapy in scabies. Indian J Dermatol. 2006;51:186\u20138.","journal-title":"Indian J Dermatol"},{"key":"1171_CR57","first-page":"e87","volume":"29","author":"S Dey","year":"2022","unstructured":"Dey S, Agarwal S, Sagar. Comparison of the effects of ivermectin, permethrin and gamma benzene hexachloride alone and with that of combination therapy for the management of scabies. J Popul Ther Clin Pharmacol. 2022;29:e87\u201396.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"1171_CR58","unstructured":"Glaziou P, Cartel J, Alzieu P, Briot C, Moulia-Pelai J, Martin P. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol. 1993;44."},{"key":"1171_CR59","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.18203\/2319-2003.ijbcp20162198","volume":"5","author":"S Kanwar","year":"2016","unstructured":"Kanwar S, Mathur S, Sankhla S. Study of efficacy of oral ivermectin in comparison to commonly used topical antiscabetic drugs gamma benzene hexachloride and permethrin. Int J Basic Clin Pharmacol. 2016;5:1234\u20138.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"1171_CR60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.66344\/jpad.v17i2.691","volume":"17","author":"I Khan","year":"2007","unstructured":"Khan I, Yasmin R. Ivermectin in the treatment of scabies. J Pak Assoc Dermatol. 2007;17:78\u201383.","journal-title":"J Pak Assoc Dermatol"},{"key":"1171_CR61","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2471\/BLT.08.052308","volume":"87","author":"F Ly","year":"2009","unstructured":"Ly F, Caumes E, Ndaw CAT, Ndiaye B, Mah\u00e9 A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: A randomized controlled trial. Bull World Health Organ. 2009;87:424\u201330.","journal-title":"Bull World Health Organ"},{"key":"1171_CR62","first-page":"201","volume":"129","author":"E Macotela-Ruiz","year":"1993","unstructured":"Macotela-Ruiz E, Pena-Gonzalez G. Tratamiento de la escabiasis con ivermectina por via oral. Gac Med Mex. 1993;129:201\u20135.","journal-title":"Gac Med Mex"},{"key":"1171_CR63","doi-asserted-by":"publisher","first-page":"54","DOI":"10.18231\/j.ijced.2021.010","volume":"7","author":"R Mallya","year":"2021","unstructured":"Mallya R, Swaroop R, Yashwanth Reddy K, Ghosh A, Krishn Z. Study of efficacy and cost effectiveness of topical permethrin, benzyl benzoate and oral ivermectin in the treatment of scabies. Indian J Clin Exp Dermatol. 2021;7:54\u201360.","journal-title":"Indian J Clin Exp Dermatol"},{"key":"1171_CR64","first-page":"1","volume":"8","author":"PK Manjhi","year":"2014","unstructured":"Manjhi PK. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res. 2014;8:1\u20134.","journal-title":"J Clin Diagn Res"},{"key":"1171_CR65","first-page":"15","volume":"3","author":"M Meenakshi","year":"2014","unstructured":"Meenakshi M, Sadhna K, Neeraj S, Deepak V, Renu P. An open label, randomized, comparative study of antiscabietic drugs permethrin, gamma benzene hexachloride and ivermectin in patients of uncomplicated scabies. Int J Pharm Clin Sci. 2014;3:15\u201321.","journal-title":"Int J Pharm Clin Sci"},{"key":"1171_CR66","first-page":"1","volume":"11","author":"C Mila-Kierzenkowska","year":"2017","unstructured":"Mila-Kierzenkowska C, Wo\u017aniak A, Krzyzy\u0144ska-Malinowska E, Ka\u0142uzna L, Weso\u0142owski R, Po\u0107wiardowski W, et al. Comparative efficacy of topical pertmehrin, crotamiton and sulfur ointment in treatment of scabies. J Arthropod Borne Dis. 2017;11:1\u20139.","journal-title":"J Arthropod Borne Dis"},{"key":"1171_CR67","first-page":"1","volume":"11","author":"B Munge","year":"2021","unstructured":"Munge B, Bodusu H, Koyagura N, Vedula P. Comparison of safety and cost-effectiveness of topical 5% permethrin and topical 1% ivermectin in patients of uncomplicated scabies. Natl J Physiol Pharm Pharmacol. 2021;11:1.","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"1171_CR68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.66344\/jpad.v20i4.382","volume":"20","author":"A Mushtaq","year":"2010","unstructured":"Mushtaq A, Khurshid K, Pal SS. Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. J Pak Assoc Dermatol. 2010;20:227\u201331.","journal-title":"J Pak Assoc Dermatol"},{"key":"1171_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/004947550103100105","volume":"31","author":"EN Nnoruka","year":"2001","unstructured":"Nnoruka EN, Agu CE. Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct. 2001;31:15\u20138.","journal-title":"Trop Doct"},{"key":"1171_CR70","first-page":"30","volume":"13","author":"A Regis Roggero","year":"2003","unstructured":"Regis Roggero A, Pancorbo Mendoza J, Lanchipa Yokota P, Regis Roggero RM, Aguero M. Treatment and reinfestation by human scabiosis: comparative study between 5% permetrin and 25% benzyl benzoate [Tratamiento y reinfestaci\u00f3n por escabiosis humana: estudio comparativo entre permetrina al 5 por ciento vs benzoato de ben. Dermatol Peru. 2003;13:30\u20133.","journal-title":"Dermatol Peru"},{"key":"1171_CR71","first-page":"128","volume":"25","author":"M Saeedi","year":"2015","unstructured":"Saeedi M, Hajheydari Z, Akbari J, Morteza-semnani K, Emadian A, Sciences P, et al. \u0631\u062f \u0628\ufeae\ufe9f \u0646\ufe8e\ufee3\u0631\u062f \ufeae\ufe91 \u0646\ufeee\ufef4\ufe97\ufefb\ufe8e\ufee3 \ufeaa\ufebb\u0631\u062f 0 \/ 5 \u0646\ufeee\ufef4\ufeb3\ufeee\ufedf \ufeae\ufe9b\u0627 \ufef2\ufeb3\u0631\ufeae\ufe91 Preparation of malathion 0.5% lotion and studying its effect on healing scabies compared with permethrin cream (\u0648 \ufeea\ufef4\ufeec\ufe97 \ufeaa\ufebb\u0631\u062f 5 \ufee6\ufef3\ufeae\ufe98\ufee3\ufeae\ufb58 \u0645\ufeae\ufedb \ufe8e\ufe91 \ufeea\ufeb4\ufef3\ufe8e\ufed8\ufee3). J Mazandaran Univ Med Sci. 2015;25:128\u201331.","journal-title":"J Mazandaran Univ Med Sci"},{"key":"1171_CR72","first-page":"45","volume":"22","author":"M Saqib","year":"2012","unstructured":"Saqib M, Malik LM, Jahangir M. A comparison of efficacy of single topical permethrin and single oral ivermectin in the treatment of scabies. J Pak Assoc Dermatol. 2012;22:45\u20139.","journal-title":"J Pak Assoc Dermatol"},{"key":"1171_CR73","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archderm.1990.01670260037006","volume":"126","author":"MW Schultz","year":"1990","unstructured":"Schultz MW, Gomez M, Hansen RC, Mills J, Menter A, Rodgers H, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol. 1990;126:167\u201370.","journal-title":"Arch Dermatol"},{"key":"1171_CR74","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4103\/0378-6323.84063","volume":"77","author":"R Sharma","year":"2011","unstructured":"Sharma R, Singal A. Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. Indian J Dermatol Venereol Leprol. 2011;77:581\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1171_CR75","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0190-9622(86)70263-6","volume":"15","author":"PD Taplin","year":"1986","unstructured":"Taplin PD, Meinking TL, Porcelain SL, Castillero PM, Chen JA. Permethrin 5% dermal cream: A new treatment for scabies. J Am Acad Dermatol. 1986;15:995\u20131001.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1525-1470.1990.tb01078.x","volume":"7","author":"D Taplin","year":"1990","unstructured":"Taplin D, Meinking TL, Chen JA, Sanchez R. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol. 1990;7:67\u201373.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1171_CR77","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0190-9622(00)90131-2","volume":"42","author":"V Usha","year":"2000","unstructured":"Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol. 2000;42(2):236\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR78","doi-asserted-by":"publisher","first-page":"633","DOI":"10.66344\/jpad.31.4.2021.1792","volume":"31","author":"A Usman","year":"2021","unstructured":"Usman A, Shehzad A, Shahid M, Saleem Z, Khawaja A, Abeer. Comparison between efficacy of topical 1% ivermectin and topical 5% permethrin in the treatment of scabies. J Pak Assoc Dermatol. 2021;31:633\u20136.","journal-title":"J Pak Assoc Dermatol"},{"key":"1171_CR79","unstructured":"Wankhade PA, Tamboli SB, Rathod P, Deshmukh JB, Shirure PA, Ghadlinge MS. Comparison of safety, efficacy, cost effectiveness of permethrin and ivermectin in patients of scabies (MIS\/PP-38). Indian J Pharmacol. 2013;45:S202."},{"key":"1171_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/0378-6323.19715","volume":"72","author":"O Zargari","year":"2006","unstructured":"Zargari O, Golchai J, Sobhani A, Dehpour AR, Sadr-ashkevari S, Alizadeh N, et al. Comparison of the efficacy of topical 1% lindane vs 5% permethrin in scabies: A randomized, double-blind study. Indian J Dermatol Venereol Leprol. 2006;72:33\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1171_CR81","unstructured":"Besa M. Precipitated sulfur 10% versus permethrin lotion 5% in the treatment of scabies in patients aged 2 months to 65 years old: An open-labeled, non-inferiority randomized controlled trial (Unpublished). Department of Family and Community Medicine. UP-PGH; 2015."},{"key":"1171_CR82","unstructured":"Macotela-Ruiz E, Mendez Islas CL, Ramos EN. Tratamiento de escabiasis con ivermectina* por via oral en una comunidad rural cerrada. lmplicaciones epidemioligicas. [Treatment of scabies with oral Ivermectin in an enclosed rural community]. Dermatol Rev Mex 40:179\u201384."},{"key":"1171_CR83","doi-asserted-by":"crossref","unstructured":"Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9:24537.","DOI":"10.1136\/bmjopen-2018-024537"},{"key":"1171_CR84","unstructured":"US Food and Drug Administration. Public Workshop: Evaluating Inclusion and Exclusion Criteria in Clinical Trials Workshop Report: The National Press Club, Washington, DC \u2022 April 16, 2018."},{"key":"1171_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Giovane C, Del, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta- analysis. PLoS Med. 2020;17:1\u201319.","journal-title":"PLoS Med"},{"key":"1171_CR86","unstructured":"Seventy-eighth World Health Assembly, World Health Organization. Skin diseases as a global public health priority. 2025 May. Report No.WHA78.15."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01171-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:45:34Z","timestamp":1789443934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01171-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01171-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This systematic review is part of the PhD dissertation of the primary investigator at the University of the Philippines College of Medicine, Department of Pharmacology and Toxicology, which was approved by the University of the Philippines Manila Research Ethics Board (UPM-REB-2022-0055-01; 09 March 2022).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We performed the network meta-analysis using R statistical software instead of Stata 16 due to the expertise of the available statistician. We included studies with various definitions of clinical cure, including partial resolution of skin lesions or composite outcomes such as itch resolution and parasitological cure together with clinical cure. We rated certainty of evidence using the three-step manual approach [39] due to technical difficulties in using the CiNEMA online software.[85]","order":4,"name":"Ethics","label":"Differences between protocol and review","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"127"}}